- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
- 个人中心
- 退出登录
浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Meta-analysis of the incidence and risk factors of anti-tuberculosis drug-induced liver injury
- ZHONGGUO YAOFANG Vol. 35, Issue 24, Pages: 3052-3058(2024)
- 作者机构：
1.重庆医科大学药学院，重庆 400016
2.重庆医科大学附属儿童医院药学部/国家儿童健康与疾病临床医学研究中心/儿童发育疾病研究教育部重点实验室/儿童发育重大疾病国家国际科技合作基地/儿童感染与免疫罕见病重庆市重点实验室，重庆 400014
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2024.24.15
CLC： R978.3;R969.3Published：30 December 2024，
Received：18 July 2024，
Revised：16 November 2024，
- 稿件说明：
移动端阅览
谢琴琴,季欢欢,龚美玲等.抗结核药物性肝损伤发生率及其危险因素的Meta分析 Δ[J].中国药房,2024,35(24):3052-3058.
XIE Qinqin,JI Huanhuan,GONG Meiling,et al.Meta-analysis of the incidence and risk factors of anti-tuberculosis drug-induced liver injury[J].ZHONGGUO YAOFANG,2024,35(24):3052-3058.
谢琴琴,季欢欢,龚美玲等.抗结核药物性肝损伤发生率及其危险因素的Meta分析 Δ[J].中国药房,2024,35(24):3052-3058. DOI： 10.6039/j.issn.1001-0408.2024.24.15.
XIE Qinqin,JI Huanhuan,GONG Meiling,et al.Meta-analysis of the incidence and risk factors of anti-tuberculosis drug-induced liver injury[J].ZHONGGUO YAOFANG,2024,35(24):3052-3058. DOI： 10.6039/j.issn.1001-0408.2024.24.15.
摘要
目的
2
系统评价抗结核药物性肝损伤（ATB-DILI）发生率及其危险因素。
方法
2
检索PubMed、Embase、the Cochrane Library、Web of Science、中国知网、维普网、万方数据、中国生物医学文献数据库，收集抗结核药物治疗结核后发生ATB-DILI及其危险因素分析的病例对照研究和队列研究，检索时限为建库至2024年5月31日。筛选文献、提取数据，评价文献质量后，采用Stata 17.0软件和RevMan 5.3软件进行Meta分析。
结果
2
共纳入26篇文献，涉及38 971例患者，其中ATB-DILI患者为4 106例。Meta分析结果显示，ATB-DILI发生率为12.94%[95%CI（10.82%，15.06%），
P
＜0.001
]
；亚组分析显示，在队列研究、中国研究、儿童患者中ATB-DILI发生率更高（
P
＜0.001）。年龄≥60岁、体重
指数异常、嗜酒、吸烟、肝病史、乙肝表面抗原阳性、肺外结核、营养不良、低蛋白血症、心血管疾病、糖尿病、系统性红斑狼疮、未预防性使用保肝药、丙氨酸转氨酶基线水平高对发生ATB-DILI均有显著影响（
P
＜0.05）。敏感性分析和发表偏倚分析结果显示，本研究所得结果稳健可靠。
结论
2
结核患者使用抗结核药物治疗后的ATB-DILI发生率为12.94%；年龄≥60岁、体重指数异常、嗜酒、吸烟、肝病史、乙肝表面抗原阳性、肺外结核、营养不良、低蛋白血症、心血管疾病、糖尿病、系统性红斑狼疮、未预防性使用保肝药、丙氨酸转氨酶基线水平高均是发生ATB-DILI的危险因素。
Abstract
OBJECTIVE
2
To systematically evaluate the incidence of anti-tuberculosis drug-induced liver injury （ATB-DILI） and its risk factors.
METHODS
2
PubMed， Embase， the Cochrane Library， Web of Science， China Knowledge Network， VIP， Wanfang data and China Biomedical Literature Database were searched to collect cohort studies and case-control studies on the incidence and risk factors of ATB-DILI from the establishment of the database to 31 May 2024. After screening literature， extracting data and evaluating the quality of literature， meta-analysis was performed using Stata 17.0 and RevMan 5.3 software.
RESULTS
2
A total of 26 literature involving 38 971 patients were included， of which 4 106 patients suffered from ATB-DILI. Meta-analysis showed that the incidence of ATB-DILI was 12.94% [95%CI （10.82%，15.06%），
P
＜0.001
]
； subgroup analysis showed that the incidence of ATB-DILI in cohort studies， Chinese studies and pediatric patients was higher （
P
＜0.001）. Age≥60 years， abnormal body mass index， alcoholism， smoking， history of liver disease， hepatitis B surface antigen positivity， extrapulmonary tuberculosis， malnutrition， hypoproteinemia， cardiovascular disease， diabetes mellitus， systemic lupus erythematosus， no prophylactic use of hepatoprotective drugs， and high baseline alanine transaminase levels were risk factors for developing ATB-DILI （
P
＜0.05）. Sensitivity analysis and publication bias analysis showed that the results obtained in this study were relatively robust.
CONCLUSIONS
2
The incidence of ATB-DILI in tuberculosis patients is 12.94%. Age≥60 years， abnormal body mass index， alcoholism， smoking， history of liver disease， hepatitis B surface antigen positivity， extrapulmonary tuberculosis， malnutrition， hypoproteinaemia， cardiovascular disease， diabetes mellitus， systemic lupus erythematosus， non-prophylactic use of hepatoprotective medications， and high baseline levels of alanine transaminase are the risk factors for developing ATB-DILI.
关键词
抗结核药药物性肝损伤发生率危险因素Meta分析
Keywords
drug-induced liver injuryincidencerisk factorsmeta-analysis
references
World Health Organization. Global Tuberculosis Report 2023[M]. Geneva：World Health Organization，2023：1-10.
中国医药生物技术协会药物性肝损伤防治技术专业委员会，中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南：2023年版[J]. 中华肝脏病杂志，2023，31（4）：355-384.
Technology Committee on DILI Prevention and Management，Chinese Medical Biotechnology Association，Study Group of Drug-Induced Liver Disease，Chinese Medical Association for the Study of Liver Diseases.Chinese guideline for diagnosis and management of drug-induced liver injury：2023 version[J]. Chin J Hepatol，2023，31（4）：355-384.
中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南：2019年版[J]. 中华结核和呼吸杂志，2019，42（5）：343-356.
Chinese Society for Tuberculosis，Chinese Medical Association.Guidelines for diagnosis and treatment of anti-tuberculosis drug-induced liver injury：2019 edition[J]. Chin J Tuberc Respir Dis，2019，42（5）：343-356.
ABBASPOUR F，HASANNEZHAD M，KHALILI H，et al. Managing hepatotoxicity caused by anti-tuberculosis drugs：a comparative study of approaches[J]. Arch Iran Med，2024，27（3）：122-126.
中华医学会结核病学分会，《中华结核和呼吸杂志》编辑委员会. 抗结核药所致药物性肝损伤诊断与处理专家建议[J]. 中华结核和呼吸杂志，2013，36（10）：732-736.
Chinese Society for Tuberculosis，Chinese Medical Association，Editorial Board of Chinese Journal of Tuberculosis and Respiratory.Expert advice on diagnosis and treatment of drug-induced liver injury caused by anti-tuberculosis drugs[J]. Chin J Tuberc Respir Dis，2013，36（10）：732-736.
STANG A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol，2010，25（9）：603-605.
梁思敏，马康，贾斌. 新疆南疆地区维吾尔族抗结核药物性肝损伤预测模型的构建[J]. 安徽医学，2024，45（5）：625-629.
LIANG S M，MA K，JIA B. Construction of prediction model of anti-tuberculosis drug-induced liver injury in Uygur in southern Xinjiang[J]. Anhui Med J，2024，45（5）：625-629.
徐璐，魏渊，卢福辉，等. 预测抗结核药物性肝损伤的卷积神经网络与logistic回归模型的建立与比较[J]. 药物不良反应杂志，2023，25（12）：705-711.
XU L，WEI Y，LU F H，et al. Development and comparison of convolutional neural network and logistic regression models for predicting anti-tuberculosis drug-induced liver injury[J]. Adverse Drug React J，2023，25（12）：705-711.
陈芳，张小佛，周海依，等. 儿童抗结核药物性肝损伤状况及相关影响因素分析[J]. 中国防痨杂志，2023，45（1）：45-51.
CHEN F，ZHANG X F，ZHOU H Y，et al. Analysis of status and influencing factors associated with anti-tuberculosis drug-related liver injury in children[J]. Chin J Antituberc，2023，45（1）：45-51.
赵鹏，陈静，杨光红，等. 住院结核患者抗结核药物性肝损伤的Nomogram风险预测模型构建[J]. 中华结核和呼吸杂志，2022，45（2）：171-176.
ZHAO P，CHEN J，YANG G H，et al. Nomogram model for predicting risk of anti-tuberculosis drug-induced liver injury among inpatients with tuberculosis[J]. Chin J Tuberc Respir Dis，2022，45（2）：171-176.
杨天池，李舒婷，陈琴，等. 宁波市肺结核患者药物性肝损伤的影响因素研究[J]. 预防医学，2022，34（2）：114-118.
YANG T C，LI S T，CHEN Q，et al. Influencing factors for drug-induced liver injury among patients with pulmonary tuberculosis in Ningbo City[J]. Prev Med，2022，34（2）：114-118.
刘芳，臧珊珊，刘永梅，等. 抗结核治疗致肺结核患者药物性肝损伤的危险因素分析[J]. 解放军医药杂志，2019，31（9）：56-59.
LIU F，ZANG S S，LIU Y M，et al. Risk factors of drug-induced hepatic injury in tuberculosis patients after anti-tuberculosis therapy[J]. Med Pharm J Chin People’s Liberation Army，2019，31（9）：56-59.
杜静，王亚东，赵彩彦. 结核病初治患者药物性肝损伤危险因素的分析[J].中华传染病杂志，2022，40（10）：602-606.
DU J，WANG Y D，ZHAO C Y. Risk factors for anti-tuberculosis drug-induced liver injury in treatment-naive tuberculosis patients[J]. Chin J Infect Dis，2022，40（10）：602-606.
杨学敏，沈宝荣，刘鹏园，等. 抗结核药致药物性肝损伤危险因素的Logistic回归分析[J]. 中国医院药学杂志，2019，39（1）：67-71.
YANG X M，SHEN B R，LIU P Y，et al. Logistic regression analysis of risk factors of antituberculosis drug-induced liver injury[J]. Chin J Hosp Pharm，2019，39（1）：67-71.
何涛，汪峰，唐武. 抗结核药致药物性肝损伤危险因素的Logistic回归分析[J]. 中国药房，2016，27（12）：1626-1628.
HE T，WANG F，TANG W. Logistic regression analysis of risk factors of antituberculosis drug-induced liver injury[J]. China Pharm，2016，27（12）：1626-1628.
马晨晨，翟啸虎，秦丽岩，等. 维吾尔族肺结核患者肝损害的发生率及相关因素的调查[J]. 中华疾病控制杂志，2016，20（1）：17-20.
MA C C，ZHAI X H，QIN L Y，et al. Study on the incidence and risk factors of liver injury in Uighur tuberculosis patients[J]. Chin J Dis Contr Prev，2016，20（1）：17-20.
周子贺. 400例初治结核患者抗结核药物致肝损伤分布特征及相关影响因素[J]. 中西医结合肝病杂志，2022，32（4）：327-330.
ZHOU Z H. Clinical Characteristics and related influen-cing factors of liver injury induced by antituberculosis drugs in 400 newly diagnosed tuberculosis patients[J]. Chin J Integr Tradit West Med Liver Dis，2022，32（4）：327-330.
毛佳斌，孙培英，徐金田. 初治肺结核患者药物性肝损伤的危险因素分析及对策[J]. 中华全科医学，2016，14（11）：1867-1869.
MAO J B，SUN P Y，XU J T. Risk factors and strategies of drug-induced liver injury in untreated pulmonary tuberculosis patients[J]. Chin J Gen Pract，2016，14（11）：1867-1869.
李文红，王芳，付莹，等. 肺结核药物性肝损害的相关因素分析[J]. 临床肺科杂志，2016，21（11）：2097-2100.
LI W H，WANG F，FU Y，et al. Analysis on liver damage of pulmonary tuberculosis patients[J]. J Clin Pulm Med，2016，21（11）：2097-2100.
朱薇珊，张斌. 抗结核药物治疗所致肝损伤的危险因素及其治疗转归分析[J]. 中国防痨杂志，2015，37（2）：167-172.
ZHU W S，ZHANG B. Preliminary clinical study on the related factors in drug-induced liver injury of anti-TB patients[J]. Chin J Antituberc，2015，37（2）：167-172.
姚雷娜，胡宾. 抗结核药物所致肝损伤的不良反应分析及风险因素研究[J]. 临床肺科杂志，2022，27（1）：62-67.
YAO L N，HU B. Analysis of adverse reactions and risk factors of liver injury caused by anti-tuberculosis drugs[J]. J Clin Pulm Med，2022，27（1）：62-67.
迟旭，漆沄，陈娟，等. 初次抗结核治疗诱发药物性肝损伤临床特点及发病危险因素的Logistic回归分析[J]. 陕西医学杂志，2019，48（1）：67-70.
CHI X，QI Y，CHEN J，et al. Logistic regression analysis of clinical characteristics and risk factors of drug-induced liver injury induced by primary anti-tuberculosis treatment[J]. Shaanxi Med J，2019，48（1）：67-70.
许光辉，陈维清，陈华，等. 抗结核药物诱导肝损伤的影响因素探讨[J]. 药物流行病学杂志，2008，17（6）：377-380.
XU G H，CHEN W Q，CHEN H，et al. Influence factors of liver injury induced by anti-tuberculosis drugs[J]. Chin J Pharmacoepidemiol，2008，17（6）：377-380.
JI S J，LU B，PAN X L. A nomogram model to predict the risk of drug-induced liver injury in patients receiving anti-tuberculosis treatment[J]. Front Pharmacol，2023，14：1153815.
JIANG F R，YAN H D，LIANG L L，et al. Incidence and risk factors of anti-tuberculosis drug induced liver injury（DILI）：large cohort study involving 4 652 Chinese adult tuberculosis patients[J]. Liver Int，2021，41（7）：1565-1575.
ABBARA A，CHITTY S，ROE J K，et al. Drug-induced liver injury from antituberculous treatment：a retrospective study from a large TB centre in the UK[J]. BMC Infect Dis，2017，17（1）：231.
SUN Q，ZHANG Q，GU J，et al. Prevalence，risk factors，management，and treatment outcomes of first-line antituberculous drug-induced liver injury：a prospective cohort study[J]. Pharmacoepidemiol Drug Saf，2016，25（8）：908-917.
LEE C M，LEE S S，LEE J M，et al. Early monitoring for detection of antituberculous drug-induced hepatotoxicity[J]. Korean J Intern Med，2016，31（1）：65-72.
ALI N，GUPTA N，SARAVU K. Malnutrition as an important risk factor for drug-induced liver injury in patients on anti-tubercular therapy：an experience from a tertiary care center in South India[J]. Drug Discov Ther，2020，14（3）：135-138.
SUBBALAXMI M V S，SOANKER R，LAKSHMI A V. Evaluation of risk factors for development of anti-tubercular therapy induced hepatotoxicity：a prospective study[J]. Curr Drug Saf，2020，15（3）：198-204.
CHENG F，QIU C C，JIANG X G，et al. Relevance of NAT2 genotype and clinical factors to risk for antituberculosis drug-induced liver injury[J]. Pharmacogenomics，2024，25（1）：21-28.
GAFAR F，ARIFIN H，JURNALIS Y D，et al. Antituberculosis drug-induced liver injury in children：incidence and risk factors during the two-month intensive phase of therapy[J]. Pediatr Infect Dis J，2019，38（1）：50-53.
中华医学会结核病学分会儿童结核病专业委员会，中国研究型医院学会结核病学专业委员会，国家呼吸系统疾病临床医学研究中心，等. 儿童结核性脑膜炎诊断专家共识[J]. 中华实用儿科临床杂志，2022，37（7）：497-501.
Pediatric Tuberculosis Speciality Committees of Society of Tuberculosis，Chinese Medical Association，Tuberculosis Speciality Committees of Chinese Research Hospital Association， National Clinical Research Center for Respiratory Diseases，et al. Expert consensus on the diagnosis of tuberculous meningitis in children[J]. Chin J Appl Clin Pediatr，2022，37（7）：497-501.
耿俊玲，张伊楠，潘洪秋. 结核病患者发生药物性肝损伤风险预测模型的构建与验证[J]. 中国防痨杂志，2024，46（6）：699-706.
GENG J L，ZHANG Y N，PAN H Q. Establishment and validation of a risk prediction model for drug-induced liver injury in patients with tuberculosis[J]. Chin J Antituberc，2024，46（6）：699-706.
于海存，杜芸辉，李玉明，等. 巨噬细胞在β肾上腺素受体过度激活致肝脏纤维化过程中的研究进展[J]. 生理科学进展，2017，48（3）：232-237.
YU H C，DU Y H，LI Y M，et al. Research progress of macrophages in the process of liver fibrosis caused by overactivation of β-adrenoceptor[J]. Prog Physiol Sci，2017，48（3）：232-237.
KESENOGILE B，GODMAN B，RWEGERERA G M. Alanine transaminase and hemoglobin appear to predict the occurrence of antituberculosis medication hepatoto-xicity；findings and implications in Botswana[J]. Expert Rev Anti Infect Ther，2021，19（3）：379-391.
0
Views
1
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.